A new direction
Improving patient outcomes
Autoimmune GI dysmotility (AGID) is a newly described clinical entity that is a clinical and limited manifestation of autoimmune dysautonomia.
Autonomic disease is typically associated with syncope, neuropathy, and sweating problems, but chronic gastrointestinal (GI) dysmotility may also be a component.
Research conducted by Mayo Clinic on autonomic disease in an immune setting led to the discovery that immunotherapy can be beneficial for patients with autonomic disease.
A treatable condition
Identifying GI dysmotility as autoimmune-mediated is extremely important, because patients treated with immunotherapy can see a dramatic improvement — going from persistent nausea, vomiting, and weight loss, to feeling normal within a few weeks.
A Test in Focus
Divyanshu (Div), Dubey, M.B.B.S., gives an overview of the new GID2 test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to previous testing approaches, and what clinical action can be taken due to the results of this testing.
Clinical clues for diagnosing AGID